VBID, the PPACA, and FREEE Medications: Did Politics Trump the Evidence About Cost Sharing?

The evidence available to date suggests that copayment reductions/waivers provided to commercially insured populations, especially when applied in primary prevention and/or to brand drugs in therapy classes with generic alternatives, are unlikely to yield meaningful health improvements and may direc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fairman, Kathleen A., Curtiss, Frederic R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2012
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438088/
https://www.ncbi.nlm.nih.gov/pubmed/22380473
http://dx.doi.org/10.18553/jmcp.2012.18.2.146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438088/
https://www.ncbi.nlm.nih.gov/pubmed/22380473
http://dx.doi.org/10.18553/jmcp.2012.18.2.146

Ejemplares similares